Further Context on AstraZeneca COVID-19 Vaccine Risks to be Provided by EMA

Pharmaceutical Technology Editors

EMA is continuing to monitor the incidences of very rare blood clots with low blood platelets occurring after vaccination with the AstraZeneca COVID-19 vaccine (Vaxzevria).

The European Medicines Agency (EMA) has confirmed, in an April 14, 2021 press release, that it is continuing to monitor the incidences of very rare blood clots with low blood platelets occurring after vaccination with the AstraZeneca COVID-19 vaccine (Vaxzevria).

A continuation of the safety review is in line with a request from the European Union’s (EU’s) Commissioner for Health and Food Safety following a meeting of EU Health Ministers. Vaccination data and data on epidemiology will be reviewed by EMA.

Through the review, which will be performed by EMA’s Committee for Medicinal Products for Human Use (CHMP), the potential risks of Vaxzevria will be put into context of the benefits for ongoing vaccination campaigns. Additionally, considerations over whether or not recommendations for a second dose of the vaccine will be considered by CHMP.

Overall, EMA considers the benefits of Vaxzevria continue to outweigh any potential risks, the agency stated in the press release. Safety and effectiveness will continue to be monitored and any updates will be provided to the public by EMA.

Source: EMA